Intellectual Property

Innovation in our hands

Screen Shot 2015-06-15 at 3.42.49 PM

The future of innovation is in our hands.

Up there with leadership and strategy, innovation is one of the most over-used words in business today, throughout the world. I challenge any CEO to define what they mean by innovation. Many don’t seem to understand it. Innovation is too valuable to be misunderstood. It’s time to change that. (more…)

Innovation: The lifeblood of the global economy

Participants perform during the opening ceremony of the 2014 Sochi Winter Olympics

Innovation is the lifeblood of the global economy, and is in its golden age. In the last decade alone, we have witnessed the introduction landmark inventions, from driverless cars, to bionic limb reconstructions, to the discovery of the Higgs Boson. That’s why it may come as a surprise that we’re reporting that year-over-year innovation growth has hit the slowest pace since the global economic recession.

A new study from our IP & Science business finds that the global pace of innovation has slowed to its lowest level since the recession. The study, which analyzes global intellectual property data — including scientific literature and patents – as a window into innovation in 12 bellwether technology areas, suggests a possible inflection point in global R&D growth in both private sector companies and academic research institutions worldwide.

Following are some of the highlights: (more…)

License to innovate: The state of patent licensing in France

A general view of the Eiffel tower and La Defense business district skyline in the background as warm and sunny weather continues in France

Last week I had the pleasure of presenting findings from a new report into intellectual property (IP) licensing at a World IP Day event in Paris. With 10.8 billion Euros estimated to be generated in the French licensing market alone, the licensing of intellectual property (IP) is a conversation starter for anyone working in the IP industry.

For those less familiar with the subject, the licensing of intellectual property rights is the process whereby an inventor forms a partnership to license IP rights for commercial gain in exchange for a fee. With that, much of the dialogue around the licensing market is taken by those arguing for a change in the law to enhance the market and make it more transparent.

But in the absence of strong data, the arguments put forward are largely based on assumptions and individual experiences so it is important to get the full pictures of the licensing market. (more…)

Trends in renewable energy inventions and oil price – Graphic of the day

Perhaps nowhere is the importance of “knowing why” more apparent than in the interplay of world energy markets and the increasing urgency of climate and environmental issues. Today’s graphic, from our 2014 Annual report, overlays the number of renewable energy inventions with price of oil.

Trends in Renewable Energy Inventions by Technology and the Rise and Fall of Oil Prices

Sources: Thomson Reuters Derwent World Patents Index, Thomson Reuters Web of Science and Thomson Reuters Datastream

Know More:


Know why: Bringing the balance between environment and energy into focus

Annual Report

2014 was a year in which knowing more —who, what, why and how — was critical to informed decision making and successful outcomes. Explore our 2014 Annual Report.

Perhaps nowhere is the importance of “knowing why” more apparent than in the interplay of world energy markets and the increasing urgency of climate and environmental issues. See how through context, connection and insight, we help professionals know why changes are occurring in world energy, identify and develop alternatives, and monitor the environmental impacts of energy: (more…)

The need to know: Explore our 2014 Annual Report

Annual Report

Our customers participate in the most important conversations in a fast and complex world every day. As professionals, they navigate markets, risks and regulations; shape and manage legal systems and tax jurisdictions; protect innovations; and drive scientific discovery. Their work is important and their decisions matter. And common to them all is the need to know.

Professionals today need more. More than information, data and news. More than speed. More than mobile access. They need insight, analysis and context. Solutions that simplify, clarify and deliver competitive advantage, providing confidence to act on what they know. And millions of professionals from every part of the global economy rely on Thomson Reuters for what they need to know to understand critical issues, solve tough problems and adapt to dynamic change.

During 2014, the risks of global fraud and rising terrorism; the multi-stage recovery of world markets and the opening up of China; the significant shift in oil prices and increasingly urgent focus on climate change and energy alternatives; and the economic and social impacts of an aging world population and Alzheimer’s disease were just a few of the challenges and opportunities facing our world. It was a year in which knowing more — who, what, why and how — was critical to informed decision making and successful outcomes.

Explore our 2014 Annual Report – Know which includes the Corporate Responsibility & Inclusion and Thomson Reuters Foundation annual reports.

The most promising drugs of 2015

Drugs to watch

In January 2014, Thomson Reuters Cortellis Competitive Intelligence named three drugs to watch that were expected to enter the market that year and make sales of over $1 billion within five years. All three entered the market as anticipated, and although the Cortellis Consensus sales forecasts have fluctuated over the course of the year, all of the drugs are still forecast to be $1 billion-plus blockbusters.

Compared with 2014, there are more potential blockbusters expected to enter the market this year. The majority of them are forecast to have 2019 sales of between $1 billion and $3 billion, although three drugs are set to exceed this, with the following 2019 sales forecasts: Bristol-Myers Squibb’s (BMS) melanoma drug Opdivo (nivolumab) at $5.684 billion; Regeneron Pharmaceuticals and Sanofi’s Praluent (alirocumab) for hypercholesterolemia at $4.414 billion; and Novartis’ LCZ-696 (sacubitril and valsartan) for chronic heart failure at $3.731 billion: (more…)

Metrics Mania

Metrics Mania

Thomson Reuters Metrics Mania, a unique competition that measures the research impact of the the 68 institutions competing in the 2015 NCAA Men’s Basketball Tournament, will align those same schools in six rounds of weekly competition to determine the final winner of the Research Crown. Winners will be identified by reports pulled from Thomson Reuters InCites.

The competition will begin Monday, March 16th and close with the naming of the champion on Tuesday, April 7th. Fans are invited to submit brackets with their predictions of the winners beginning March 16. Participants will be awarded one point for each correct guess. At the conclusion of the contest, the 10 entrants with the most points will each be awarded a $100 American Express Gift Card.

Get notified when brackets are available.

Follow Metrics Mania on Twitter @InCites_TR and join the conversation at #metricsmania.


The meaning

Hear from our global employees what working at Thomson Reuters means to them. These employees support offerings associated with the lifecycle of innovation, enabling today’s agents of change through the discovery, protection and commercialization of their ideas and brands.

Interested in working at Thomson Reuters? Come join our global team.

Cochlear – Partners in Innovation

A case study on how Thomson Reuters helps Cochlear achieve their innovation goals and manage their intellectual property workflow.

Learn more about our IP & Science business.